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Summary
 
In the central nervous system, interleukin (IL)-3 has been shown to exert a trophic action only
on septal cholinergic neurons in vitro and in vivo, but a widespread distribution of IL-3 recep-
tor (IL-3R) in the brain does not conform to such a selective central action of the ligand.
Moreover, the mechanism(s) underlying the neurotrophic action of IL-3 has not been eluci-
dated, although an erythroleukemic cell line is known to enter apoptosis after IL-3 starvation
possibly due to a rapid decrease in Bcl-2 expression. This in vivo study focused on whether IL-3
rescued noncholinergic hippocampal neurons from lethal ischemic damage by modulating the
expression of Bcl-x
 
L
 
, a Bcl-2 family protein produced in the mature brain. 7-d IL-3 infusion
into the lateral ventricle of gerbils with transient forebrain ischemia prevented significantly hip-
pocampal CA1 neuron death and ischemia-induced learning disability. TUNEL (terminal
deoxynucleotidyltransferase–mediated 2
 
9
 
-deoxyuridine 5
 
9
 
-triphosphate-biotin nick end label-
ing) staining revealed that IL-3 infusion caused a significant reduction in the number of CA1
neurons exhibiting DNA fragmentation 7 d after ischemia. The neuroprotective action of IL-3
appeared to be mediated by a postischemic transient upregulation of the IL-3R 
 
a 
 
subunit in
the hippocampal CA1 field where IL-3R
 
a 
 
was barely detectable under normal conditions. In
situ hybridization histochemistry and immunoblot analysis demonstrated that Bcl-x
 
L
 
 mRNA
expression, even though upregulated transiently in CA1 pyramidal neurons after ischemia, did
not lead to the production of Bcl-x
 
L
 
 protein in ischemic gerbils infused with vehicle. However,
IL-3 infusion prevented the decrease in Bcl-x
 
L
 
 protein expression in the CA1 field of ischemic
gerbils. Subsequent in vitro experiments showed that IL-3 induced the expression of Bcl-x
 
L
 
mRNA and protein in cultured neurons with IL-3R
 
a 
 
and attenuated neuronal damage caused
by a free radical–producing agent FeSO
 
4
 
. These findings suggest that IL-3 prevents delayed
neuronal death in the hippocampal CA1 field through a receptor-mediated expression of Bcl-
x
 
L
 
 protein, which is known to facilitate neuron survival. Since IL-3R
 
a 
 
in the hippocampal
CA1 region, even though upregulated in response to ischemic insult, is much less intensely ex-
pressed than that in the CA3 region tolerant to ischemia, the paucity of IL-3R interacting with
the ligand may account for the vulnerability of CA1 neurons to ischemia.
Key words: interleukin 3 • transient forebrain ischemia • DNA fragmentation • receptor •
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I
 
nterleukin (IL)-3, identified as a T cell–derived cytokine,
affects the proliferation of hematopoietic progenitor cells
at early stages of their differentiation (1). It also possesses a
potent macrophage-activating action which is associated with
T cell–dependent immune responses (2, 3) and stimulates
the differentiation of stem cells and various cell types originat-
ing in bone marrow (4, 5). A single receptor for IL-3 has been
postulated (6), and IL-3 acts on cells possibly through binding
to the surface receptor. The receptor is composed of 
 
a 
 
and 
 
b
 
subunits; the 
 
a 
 
subunit is responsible for binding of IL-3,
and the ligand-activated 
 
a 
 
subunit is associated with the 
 
b 
 
sub-
unit, which transmits signals across the plasma membrane (7).
Recent studies have demonstrated the possibility that IL-3
functions in the central nervous system. Frei et al. (8, 9)
found that IL-3 stimulates the growth and proliferation of
microglial cells in vitro. Moroni and Rossi (10) demon-
strated that IL-3 facilitates significantly the survival of sen-
sory neurons and stimulates the formation of the neural
network in vitro. Kamegai et al. (11) also showed that IL-3
promotes the process extension of cultured cholinergic
  
636
 
Neurotrophic Activity of IL-3
 
neurons without affecting somatostatin release, glutamate
decarboxylase activity, or 2
 
9
 
,3
 
9
 
-cyclic nucleotide 3
 
9
 
-phos-
phodiesterase activity and rescues axotomized cholinergic
neurons from degeneration, suggesting a protective effect
of IL-3 specifically on cholinergic neurons. However, the
mechanism(s) by which IL-3 supports neurons has not yet
been determined. Moreover, it remains unsolved whether
or not IL-3 exhibits a trophic action on neuronal cells
other than septal cholinergic neurons in vivo. Since IL-3R
and its associated antigens are distributed in a variety of
brain regions, including the hippocampus, despite un-
known localization of the ligand in the brain (7, 12–14) IL-3
is expected to exert a central action in brain areas apart
from the septum containing cholinergic neurons.
Upon withdrawal of IL-3, the erythroleukemic cell line
TF-1 has been shown to enter apoptosis as a result of de-
creased production of Bcl-2 mRNA and protein (15). Fur-
thermore, the expression of Bcl-2 protein is known to at-
tenuate oxygen free radical cytotoxicity (16, 17). Since
Bcl-x
 
L
 
 is an apoptosis-inhibiting agent of the Bcl-2 family
(18–20) and is expressed mainly in the mature brain (21,
22), we speculated that IL-3 exhibited neurotrophic action
by inducing Bcl-x
 
L
 
 expression. In this in vivo study, we in-
vestigated whether IL-3 rescued hippocampal CA1 neu-
rons from lethal ischemic damage, using the gerbil fore-
brain ischemia model. This animal model exhibits an
invariable CA1 neuron damage and abnormal behavior 7 d
after ischemia, and thus appears to be suitable for studying
the neurotrophic actions of peptide growth factors in vivo
(23–25). Although excitotoxins, including 
 
N
 
-methyl-
 
d
 
-aspar-
tate and kainic acid, can also be used to damage hippo-
campal CA1 and/or CA3 neurons (26, 27), the excito-
toxin-induced neuronal degeneration is not necessarily
identical to ischemic neuronal death, which is caused by
multiple factors such as free radicals, excess extracellular
glutamate, hypoxia, and glucose deficiency (28–31), and it
may be a rather artificial model for neuron death compared
with the gerbil ischemia model. Therefore, we chose the
gerbil ischemia model as a tool to examine the central action
of IL-3. In ischemic gerbils with or without intracere-
broventricular IL-3 infusion, CA1 neuron density, volume
of the CA1 pyramidal cell layer, learning ability, CA1 syn-
apse number, DNA fragmentation of CA1 neurons, and lo-
cal expressions of IL-3R
 
a
 
 and Bcl-x
 
L
 
 were investigated.
Subsequently, the culture experiments concentrated on
whether or not IL-3 enhanced neuronal survival through a
receptor-mediated induction of Bcl-x
 
L
 
 expression and pro-
tected neurons against oxidative injury induced by FeSO
 
4
 
.
The latter in vitro experiment was based on the notion that
oxygen free radicals are, at least in part, responsible for delayed
neuronal death in the hippocampal CA1 field (28, 32–34).
 
Materials and Methods
 
In Vivo Ischemia Study
 
Osmotic Minipump Implantation.
 
Male Mongolian gerbils weigh-
ing 70–80 g (
 
z
 
12 wk of age) were used in the in vivo study. The
following experiments were conducted in accordance with the
Guide for Animal Experimentation at Ehime University School
of Medicine. The animals were anesthetized with 1.5% halothane
in a 4:3 mixture of nitrous oxide and oxygen and placed in a ster-
eotaxic apparatus. An osmotic minipump (model 2001; Alza
Corp., Palo Alto, CA) was implanted subcutaneously into the
back of each animal, and a needle from the minipump was placed
in the left lateral ventricle at the point 1.5 mm anterior, 1.0 mm
lateral, and 2.7 mm ventral to bregma as illustrated in the atlas of
Thiessen and Yahr (35).
 
Preischemic Infusion of IL-3.
 
Recombinant murine IL-3 (Pepro-
Tech, Inc., Rocky Hill, NJ) was dissolved in 0.05 M PBS con-
taining 0.1% BSA (Sigma Chemical Co., St. Louis, MO). IL-3
(64 or 320 ng/d) or vehicle was infused for 7 d into the left lateral
ventricles of normothermic gerbils exposed to 3-min forebrain
ischemia (
 
n
 
 
 
5
 
 6–8 in each group). The molar concentrations of
infused IL-3 were similar to those of the other growth factors ex-
amined to date in the same gerbil ischemia model (23–25). Sham-
operated animals received vehicle infusion (
 
n
 
 
 
5
 
 8). The infusion
was started 2 h before an ischemic insult as described elsewhere
(23–25, 36, 37).
 
Postischemic Infusion of IL-3.
 
To investigate the effect of post-
ischemic treatment with IL-3 on delayed neuronal death, 5.3 or
26.5 ng of IL-3 in 2 
 
m
 
l of vehicle was injected into the left lateral
ventricle through a Hamilton syringe immediately after 3-min
forebrain ischemia, and then IL-3 (64 or 320 ng/d) was continu-
ously infused for 7 d into the cerebral ventricles as described
above (
 
n
 
 
 
5
 
 8 in each group). In control experiments, ischemic
animals received vehicle infusion (
 
n
 
 
 
5
 
 8).
 
Occlusion of the Common Carotid Arteries.
 
Occlusion of the com-
mon carotid arteries was performed as described previously (38).
In brief, both common carotid arteries were exposed through a
ventral midline incision and separated carefully from the adjacent
veins and nerves while the gerbil was anesthetized as described
above. Immediately after the termination of inhalation anesthesia,
the common carotid arteries were clamped for 3 min with aneu-
rysm clips.
During forebrain ischemia, brain temperature has been shown
to fall differently in individual animals, thereby affecting the
number of viable CA1 neurons after ischemia (38, 39). To avoid
the effect of unstable brain temperature on ischemic neuronal
loss, we kept brain and rectal temperatures at 37.0 
 
6
 
 0.2
 
8
 
C while
clamping the common carotid arteries (23–25, 36–39). This en-
abled us to induce an invariable neuronal damage in the hippo-
campal CA1 field even after a 3-min ischemic insult (23–25, 36,
37) and to evaluate accurately the in vivo effects of IL-3 on de-
layed neuronal death.
 
Passive Avoidance Task.
 
7 d after forebrain ischemia, the ger-
bils were trained in a conventional step-down passive avoidance
apparatus that was divided into a safe platform and a foot-shock
chamber with a stainless steel grid floor (40). Each animal was
placed initially on the safe platform, but if the gerbil stepped
down onto the grid floor, it received a foot shock. After repeated
movements between the platform and the grid, the gerbil eventu-
ally stayed on the platform. This training session lasted 300 s. 24 h
later, the gerbil was again placed on the safe platform while the
shock generator was turned off, and the response latency, i.e., the
time until it stepped down onto the grid floor, was measured.
This test session also lasted 300 s. Each animal received only one
training session and only one test session (23–25, 36, 37).
 
Histopathological Study of Hippocampal CA1 Region.
 
1 h after the
passive avoidance experiments, each animal was anesthetized with
pentobarbital, and the osmotic minipump was disconnected from 
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the needle placed in the left lateral ventricle. Bromphenol blue
was injected through the needle to ascertain the infusion of IL-3
or vehicle into the cerebral ventricles. The animals were perfused
transcardially with 4% paraformaldehyde and 2.5% glutaraldehyde
in 0.1 M phosphate buffer (pH 7.4; reference 38). A brain region
including the dorsal hippocampus from 0.5 to 1.5 mm posterior to
bregma was excised and kept in the same fixative overnight at
4
 
8
 
C. Four serial coronal sections (50 
 
m
 
m thick at the level of 1.0–
1.2 mm posterior to bregma) from the brains of gerbils infused
with IL-3 or vehicle before ischemia were cut with a microslicer
(Dosaka EM Co., Ltd., Kyoto, Japan). The remaining dorsal hip-
pocampus and the dorsal hippocampus of gerbils infused with IL-3
or vehicle after ischemia were embedded in paraffin, and 5-
 
m
 
m serial
frontal sections were cut and stained with 0.1% cresyl violet. All
neurons with intact morphological appearance along 1 mm linear
length of the hippocampal CA1 field in six serial paraffin sections
(1.20–1.23 mm posterior to bregma) were counted in each ani-
mal. The volume of the pyramidal cell layer along 1.5 mm linear
length of the hippocampal CA1 field was also measured in the six
paraffin sections from each animal (measuring system MS3000;
Mitsubishi Chemical Corp., Tokyo, Japan). For electron micros-
copy, the 50-
 
m
 
m sections were postfixed with 1% osmium tetroxide
for 30 min, dehydrated with a graded series of ethanol, transferred
to propylene oxide, and embedded in epoxy resin. The strata
moleculare, radiatum, pyramidale, and oriens of the CA1 field
were identified in semithin sections stained with 1% toluidine blue,
and ultrathin sections 70-nm thick were cut with a Reichert-Jung
ultramicrotome (C. Reichert Optische Werke AG, Vienna, Aus-
tria) and mounted on single-slot (2 
 
3
 
 0.5 mm) grids coated with
formvar film. They were subjected to dual staining with uranyl
acetate and lead citrate, and examined with a transmission electron
microscope (model H-12A; Hitachi Ltd., Tokyo, Japan). Electron
micrographs of the central area (15 
 
m
 
m 
 
3
 
 18.75 
 
m
 
m 
 
5
 
 280 
 
m
 
m
 
2
 
)
of each stratum were taken, and intact synapses with thick ap-
posed membranes and synaptic vesicles in the area were counted.
The fine structure of the stratum pyramidale in the CA1 field was
also observed in ischemic gerbils with or without IL-3 infusion.
 
In Situ Detection of DNA Fragmentation (TUNEL Staining).
 
To analyze quantitatively the changes in the nuclear chromatin of
the hippocampal CA1 neurons as revealed by electron micros-
copy, we conducted in situ detection of DNA fragmentation us-
ing TUNEL (terminal deoxynucleotidyltransferase–mediated
2
 
9
 
-deoxyuridine 5
 
9
 
-triphosphate-biotin nick end labeling)
 
1
 
 stain-
ing. Animals infused with IL-3 (64 or 320 ng/d) or vehicle (
 
n
 
 
 
5
 
6–8 in each group) before ischemia were perfused with 4%
paraformaldehyde in 0.1 M phosphate buffer (pH 7.4) under pen-
tobarbital anesthesia after passive avoidance experiments. The
number of neurons and the volume of the pyramidal cell layer of
the hippocampal CA1 region in each animal were determined as
described above, and two additional paraffin sections from each
animal were processed for TUNEL staining to estimate the num-
ber of degenerating CA1 neurons after 7 d infusion of IL-3 or ve-
hicle. In brief, the sections were deparaffinized in xylene and in a
graded series of ethanol; incubated with 20 
 
m
 
g/ml of proteinase
K (Sigma Chemical Co.) in 0.05 M PBS for 15 min; incubated
with equilibration buffer (In Situ Apoptosis Detection kit; Oncor
 
Inc., Gaithersburg, MD) for 5 min, and then incubated in a mix-
ture of terminal deoxynucleotidyltransferase and reaction buffer
containing digoxigenin-2
 
9
 
-deoxyuridine 5
 
9
 
-triphosphate-biotin
in a humidified chamber for 1 h at 37
 
8
 
C; washed in wash buffer
for 10 min and incubated with anti-digoxigenin peroxidase for 1 h
at room temperature; and rinsed three times in PBS for 5 min
each, and exposed to 0.05% diaminobenzidine and 0.02% hydro-
gen peroxide. All TUNEL-positive neurons along 1 mm linear
length of the CA1 field in the two serial coronal sections were
counted, and the mean number of positive neurons was calcu-
lated in each animal.
 
Immunohistochemical Analysis of Ischemic Hippocampal CA1 Neu-
rons with an Anti–IL-3R Antibody.
 
At 1, 2, 4, and 7 d after 3-min
ischemia, the gerbils with or without IL-3 infusion were anesthe-
tized with pentobarbital and perfused transcardially with 4%
paraformaldehyde (
 
n
 
 
 
5
 
 4 in each group). The brains were excised
and immersed overnight in 0.1 M phosphate buffer (pH 7.4) con-
taining 30% sucrose at 4
 
8
 
C. Serial frozen sections 30 
 
m
 
m thick
were cut with a cryostat and processed for immunohistochemistry
with an affinity-purified rabbit antibody against IL-3R
 
a 
 
(Santa
Cruz Biotechnology, Inc., Santa Cruz, CA). In brief, the sections
were washed with 0.1 M PBS for 30 min and incubated with the
IL-3R
 
a
 
 antibody diluted 1:100 with PBS containing 1% normal
swine serum and 0.1% Triton X-100 for 48 h at 4
 
8
 
C; incubated
with biotinylated anti–rabbit IgG and peroxidase-conjugated
streptavidin (DAKO A/S, Glostrup, Denmark) overnight at 4
 
8
 
C;
and subjected to a modified version of the cobalt-glucose oxidase-
diaminobenzidine intensification method (41). In control experi-
ments, cryosections were incubated with the IL-3R
 
a
 
 antibody,
which had been adsorbed with an excess of the homologous anti-
gen (Santa Cruz Biotechnology, Inc.), and were processed as de-
scribed above. Some sections were directly incubated with the
second antibody without any preincubation.
 
Immunoblot Analysis of the Hippocampal CA1 Field with IL-3R
 
a
 
and Bcl-x
 
L
 
 Antibodies.
 
Homogenates of the hippocampal CA1
field were obtained from sham-operated and ischemic gerbils 1,
2, and 4 d after 3-min ischemia (
 
n
 
 
 
5
 
 4 in each group). They were
solubilized in a sample solution containing 2% SDS, and an equal
amount of protein (40 
 
m
 
g) in the homogenates was electropho-
resed in individual lanes using 6% polyacrylamide gel in the
Laemmli’s buffer system (42). Protein concentration was deter-
mined by BCA protein assay reagent (Pierce Chemical Co.,
Rockford, IL) with BSA as a standard. The electrophoretic bands
were transferred to nitrocellulose sheets (43) and immunoblotted
with the IL-3R
 
a 
 
antibody or with a mouse mAb against Bcl-x
 
L
 
protein (Transduction Laboratories, Inc., Lexington, KY). Anti–
rabbit or anti–mouse IgG coupled with alkaline phosphatase
(Promega Corp., Madison, WI) was used for the second immu-
noreaction. The immunoreactive bands were visualized as de-
scribed elsewhere (44). Prestained molecular weight markers
were purchased from Bio-Rad Laboratories (Richmond, CA).
Immunoblot analysis with the Bcl-x
 
L
 
 antibody was also con-
ducted using homogenates of the ischemic hippocampal CA1
field treated with IL-3. The immunoblot analyses were repeated
three times.
 
In Situ Hybridization Histochemistry for Detection of Bcl-x
 
L
 
 mRNA.
 
To detect gerbil Bcl-x
 
L
 
 mRNA, we determined a DNA sequence
specific for gerbil Bcl-x
 
L
 
 using reverse transcription (RT)-PCR.
Based on this data, an oligonucleotide probe was designed and
synthesized (Pharmacia Biotech AB, Uppsala, Sweden). The
probe (5
 
9
 
-GGTGGTCATTCAGGTAGGTGGCCATCCAAC
TTGCG-3
 
9
 
) corresponds to the bases 498–532 of mouse Bcl-x
 
L
 
mRNA. Computer-assisted homology searches (GenBank and
 
1
 
Abbreviations used in this paper:
 
 MAP2, microtubule-associated protein 2;
RT, reverse transcription; TBS, Tris-buffered saline; TUNEL, terminal
deoxynucleotidyltransferase–mediated 2
 
9-deoxyuridine 59-triphosphate-
biotin nick end labeling.638 Neurotrophic Activity of IL-3
EMBL updates, December 1997) showed that the probe shared
no homology with any sequences contained in the gene bank. 1,
2, 4, and 7 d after 3-min ischemia, the gerbils were anesthetized
with pentobarbital and decapitated. The brains were excised and
immediately frozen on powdered dry ice. Serial sections 15-mm
thick were cut on a cryostat, thaw-mounted onto polysilane-
coated slides, and stored at 2808C until use. The sections were
fixed with 4% paraformaldehyde in 0.1 M phosphate buffer (pH
7.2) for 15 min at room temperature, rinsed three times (5 min
each) in 43 SSC (pH 7.2; 13 SSC contained 0.15 M sodium
chloride and 0.015 M sodium citrate), and dehydrated through a
graded series of ethanol. The sections were then treated with
chloroform for 5 min and immersed in 100% ethanol twice for 5
min each. Hybridization was performed by incubating the sec-
tions with a buffer (43 SSC, 50% deionized formamide, 0.12 M
phosphate buffer, pH 7.2, Denhardt’s solution, 2.5% tRNA, 10%
dextran sulfate) containing [a-35S]dATP (37–55.5 TBq/mmol;
NEN Research Products, Boston, MA)–labeled probes for 24 h
at 418C (1–2 3 107 dpm/ml, 0.3 ml/slide). After hybridization,
the sections were rinsed in 13 SSC (pH 7.2) for 10 min, fol-
lowed by rinsing three times in 13 SSC at 558C for 20 min each.
The sections were then dehydrated through a graded series of
ethanol and exposed at room temperature for 2 d using an image
analyzer (model BAS-3000; Fuji Photo Film Co., Tokyo, Japan),
followed by coating with NBT-5 emulsion (Eastman Kodak Co.,
Rochester, NY) diluted 1:1 with water. They were exposed to
the emulsion at 48C for 4 wk in a tightly sealed dark box, devel-
oped in D-19 developer (Eastman Kodak Co.), and counter-
stained with thionin solution. Relative changes in Bcl-xL mRNA
expression were quantified by determining, with the NIH image
analysis system, the ratio of the optical density in the ischemic
CA1 field to that in the control (sham-operated) CA1 field.
In Vitro Culture Experiments
Cortical and Hippocampal Neuron Cultures. The cerebral cortex
and hippocampus of 17-d-old rat embryos were aseptically dis-
sected out. Cortical and hippocampal neurons were dissociated
from the tissues as described elsewhere (44). The dissociated cells
were seeded on 24-well plastic plates (Corning Glass Works,
Corning, NY) coated with poly-l-lysine at a density of 3–5 3
104 cells/cm2. The cells were cultured at 378C in DMEM (Iwaki
Glass Co., Ltd., Tokyo, Japan) supplemented with 10% FCS
(GIBCO BRL, Gaithersburg, MD) under an atmosphere of 5%
CO2 and nearly 100% humidity.
IL-3 Treatment. On day 2 of culture, the culture medium was
replaced with serum-free DMEM containing 0–15 ng/ml of
IL-3, 20 mM Hepes, 0.45% glucose, 5 mg/ml pig insulin (Boeh-
ringer Mannheim, Mannheim, Germany), 5 mg/ml human trans-
ferrin (Boehringer Mannheim), 5 ng/ml sodium selenite (Boeh-
ringer Mannheim), 25 nM progesterone (Sigma Chemical Co.),
and 0.1% BSA. The concentrations of IL-3 chosen in these in
vitro studies were similar to those used in the study of Kamegai et
al. (11). The cultures were maintained for 3 d.
Immunocytochemical Staining of IL-3Ra in Cultured Neurons.
On day 4 of culture with or without IL-3 treatment, the neurons
were rinsed and fixed with 4% paraformaldehyde in PHEM
buffer (60 mM Pipes, 25 mM Hepes, 1 mM EDTA, and 2 mM
MgCl2, pH 6.9; reference 45) and processed for immunocy-
tochemical staining with the IL-3Ra antibody. In brief, the cul-
tured neurons were washed with 20 mM Tris-buffered saline
(TBS) and incubated for 30 min at 378C with the primary anti-
body diluted 1:100 with TBS containing 1% normal goat serum
and 0.02% Triton X-100. After rinsing with TBS containing
0.02% Triton X-100, the neurons were incubated with alkaline
phosphatase–conjugated goat anti–rabbit IgG (Promega Corp.)
for 1 h at 378C. The IL-3Ra immunoreactivity was visualized as
described elsewhere (44).
Microtubule-associated Protein 2 Staining of Cultured Neurons.
One third of the cultured neurons were fixed with PHEM buffer
containing 4% paraformaldehyde. They were then processed for
immunohistochemical staining with an mAb against microtubule-
associated protein 2 (MAP2), which is known to be a specific
neuronal marker (Sternberger Monoclonals Inc., Baltimore, MD).
In brief, the cultured neurons were washed with TBS for 30 min
and incubated with the MAP2 antibody diluted 1:1,000 with
TBS containing 1% normal goat serum and 0.3% Triton X-100
for 48 h at 48C; incubated with biotinylated anti–mouse IgG and
peroxidase-conjugated streptavidin (DAKO A/S) overnight at
48C; and subjected to a modified version of the cobalt-glucose
oxidase-diaminobenzidine intensification method (41). MAP2-
positive neurons in four randomly selected fields (1 mm2 per
field) of individual cultures were counted.
Immunoblot Analysis of Cultured Neurons. The cells from each
well not processed for MAP2 immunohistochemical staining
were solubilized in a sample solution containing 2% SDS. For
MAP2 immunoblot, the final volume was adjusted to 100 ml, and
15 ml of the sample was electrophoresed into each lane using 6%
polyacrylamide gel in the Laemmli’s buffer system (42). For Bcl-xL
immunoblot, the final concentration of protein was adjusted to
50 mg/ml, and 20 ml of the sample was electrophoresed. The
electrophoretic bands were immunoblotted with the anti-MAP2
or Bcl-xL antibody. For quantitative evaluation, the immunoreac-
tive bands were subjected to densitometric analysis with a combi-
nation of Adobe Photoshop and the NIH image analysis system (46).
Analysis of Bcl-xL mRNA Expression in Cultured Neurons. To-
tal RNA was extracted from cortical neurons cultured with 0–10
ng/ml of IL-3 using Isogen (Nippon Gene Co., Ltd., Tokyo, Japan),
and was treated with DNase. Oligo dT primers together with 3 mg
of DNase-treated total RNA and Moloney murine leukemia virus
reverse transcriptase (GIBCO BRL) were used to obtain single-
strand DNA. PCR was conducted using Taq polymerase (TaKaRa,
Tokyo, Japan). The following conditions were used for PCR am-
plification: cDNA products of the reverse transcription reaction
were denatured for 2 min at 948C before 20 cycles (for b-actin) or
25 cycles (for Bcl-xL) at 948C for 1.5 min, 558C for 1.5 min, and
728C for 2 min. The RT-PCR products were separated on 3% aga-
rose gel and visualized with ethidium bromide. Quantification of
the PCR bands was done using the NIH image analysis system. The
following pairs of oligonucleotides corresponding to certain se-
quences within the coding regions of Bcl-xL and b-actin genes were
used as primers: rat Bcl-xL primers, 59 primer (59-GTAGTGAAT-
GAACTCTTTCGGGAT-39) and 39 primer (59-CCAGCCGC-
CGTTCTCCTGGATCCA-39); and rat b-actin primers, 59 primer
(59-AGAAGAGCTATGAGCTGCCTGACG-39) and 39 primer
(59-TACTTGCGCTCAGGAGGAGCAATG-39).
FeSO4-induced Oxidative Damage. To introduce oxidative dam-
age to cultured neurons from cortex or hippocampus, freshly pre-
pared 10 or 90 mM FeSO4 solution, respectively, was added to
the medium on day 3 of culture with or without IL-3 pretreat-
ment (47–51). The cortical neuron cultures were maintained for
2 h and the hippocampal neuron cultures for 24 h at 378C. MAP2
staining and MAP2 immunoblot analysis were then conducted as
described above.639 Wen et al.
Statistics
All experiments were done blindly with respect to experimen-
tal group. The two-tailed Mann-Whitney U-test was used to
evaluate the effects of IL-3 in vivo. Statistical analyses for the in
vitro culture experiments and in situ hybridization histochemistry
were conducted using analysis of variance followed by Fisher’s
post hoc test (PLSD). All data were represented as mean 6 SD.
Results
Effects of IL-3 on CA1 Neuronal Density, Volume of the
CA1 Pyramidal Cell Layer, and Response Latency In Vivo.
We first investigated CA1 neuronal density, volume of the
CA1 pyramidal cell layer, and response latency in sham-
operated and ischemic gerbils with vehicle infusion to as-
certain that they were significantly reduced by a 3-min
ischemic insult. The mean CA1 neuronal density and vol-
ume of the pyramidal cell layer along 1.5 mm linear length
of the hippocampal CA1 field in sham-operated animals
were 248.7 6 12.4 cells/mm and 0.390 6 0.02 mm3/per
section, respectively, and those of 3-min ischemic gerbils
infused with vehicle alone were 127.3 6 31.5 cells/mm and
0.268 6 0.03 mm3/per section, respectively. The mean re-
sponse latency in sham-operated animals was 230.8 6 40.5 s,
and that in vehicle-infused ischemic gerbils was 124.5 6
28.8 s. There were significant differences in CA1 neuronal
density (U 5 0, P ,0.01), volume of the CA1 pyramidal
cell layer (U 5 0, P ,0.01), and response latency (U 5 0,
Figure 1. (A and B) Effects of intracerebroventricular IL-3 infusion on CA1 neuronal density (A) and volume of the CA1 pyramidal cell layer (B) in isch-
emic gerbils. The infusion of IL-3 started 2 h before or just after 3-min ischemia, and continued for 7 d. Significant dose-dependent increases in CA1 neu-
ronal density and volume of the CA1 pyramidal cell layer were noted in IL-3–infused ischemic gerbils compared with vehicle-infused ischemic animals.
(C) Effect of IL-3 infusion on response latency in the passive avoidance task. The infusion of IL-3 significantly prolonged the response latency in a dose-
dependent manner in ischemic gerbils compared with vehicle infusion. Each column in A–C represents mean 6 SD (n 5 6–8). *P ,0.05, **P ,0.01,
Significantly different from the corresponding vehicle-infused ischemic group (statistical significance tested by the two-tailed Mann-Whitney U-test).
(D–G) Photomicrographs of the hippocampal CA1 field: sham-operated animal infused with vehicle (D); ischemic animal infused with vehicle (E); isch-
emic animal infused with 64 ng/d of IL-3 (F); ischemic animal infused with 320 ng/d of IL-3 (G). Note that the infusion of IL-3, starting 2 h before
3-min ischemia, rescued a significant number of hippocampal CA1 pyramidal neurons. Sections were stained with 0.1% cresyl violet. Bar 5 100 mm. (H)
Positive correlation between the response latency in the passive avoidance task and the neuronal density of the hippocampal CA1 field, as evaluated by
Pearson product–moment correlation analysis.640 Neurotrophic Activity of IL-3
P ,0.01) between the two groups (Fig. 1, A–C). In histo-
logical sections, the CA1 region of ischemic gerbils exhib-
ited a marked decline in viable neurons compared with the
CA1 field of sham-operated animals (Fig. 1, D and E).
We next investigated whether IL-3 treatment prevented
the ischemia-induced decreases in CA1 neuronal density
and volume of the CA1 pyramidal cell layer. Hippocampal
CA1 neurons in ischemic gerbils infused with IL-3, starting
2 h before ischemia, outnumbered significantly those in isch-
emic gerbils infused with vehicle (64 or 320 ng/d of IL-3
versus vehicle in ischemic gerbils: U 5 20, P ,0.05, or U 5
6, P ,0.01, respectively [Fig. 1, A, F, and G]). The vol-
ume of the CA1 pyramidal cell layer per section was also
significantly larger in the IL-3–treated than in vehicle-
treated ischemic gerbils (64 or 320 ng/d of IL-3 versus ve-
hicle in ischemic gerbils: U 5 12, P ,0.05, or U 5 1, P
,0.01, respectively [Fig. 1 B]).
The prevention by IL-3 infusion of ischemic neuronal
damage in the hippocampal CA1 field was further rein-
forced by the results of passive avoidance tests. The infu-
sion of IL-3, starting 2 h before ischemia, caused a signifi-
cant dose-dependent prolongation in response latency in
the step-down passive avoidance task (64 or 320 ng/d of
IL-3 versus vehicle in ischemic gerbils: U 5 20, P ,0.05,
or U 5 4, P ,0.01, respectively [Fig. 1 C]). The results of
passive avoidance experiments correlated well with the
neuronal density of the hippocampal CA1 region in sham-
operated and ischemic gerbils infused with vehicle or IL-3
(r 5 0.770, P ,0.05 [Fig. 1 H]).
The effect of postischemic treatment with IL-3 on de-
layed neuronal death was also investigated. IL-3 infusion in
a dose of 64 or 320 ng/d for 7 d, starting just after 3-min
ischemia, also prevented the ischemia-induced decreases in
the number of CA1 neurons and volume of CA1 field (64
Figure 2. (A) Effect of IL-3 on the number of intact synapses in the three strata of the hippocampal CA1 region. The infusion of IL-3 or vehicle was
started 2 h before 3-min ischemia, and continued for 7 d. Intact synapses in the strata radiatum (sr), moleculare (sm), and oriens (so) of the hippocampal
CA1 region of ischemic gerbils with vehicle infusion were less numerous than in the strata of sham-operated (sham-op) animals, and the decrease in intact
synapse number in the ischemic hippocampus was prevented significantly when IL-3 (64 or 320 ng/d) was infused into the lateral ventricle for 7 d. Each
column represents mean 6 SD (n 5 6–8). *P ,0.05, **P ,0.01, Significantly different from the ischemic group with vehicle infusion (statistical signifi-
cance tested by the two-tailed Mann-Whitney U-test). (B–D) Electron micrographs of the soma of ischemic hippocampal CA1 neurons treated with ve-
hicle (B and C) or 320 ng/d of IL-3 (D). Note that the hippocampal CA1 pyramidal neurons in the vehicle- but not IL-3–treated ischemic gerbils were
in the course of nuclear chromatin fragmentation and/or condensation (C), and that the cell nucleus of a vehicle-treated ischemic neuron at an early stage
of degeneration (B) had an irregular euchromatin with electron density lower than that of an intact nuclear euchromatin (D). Bar 5 5 mm.641 Wen et al.
or 320 ng/d of IL-3 versus vehicle in ischemic gerbils: U 5 10,
P ,0.05, U 5 8.5, P ,0.05; or U 5 7, P ,0.01, U 5 0.5,
P ,0.01, respectively) and caused a significant prolongation
in response latency compared with that of vehicle-treated
ischemic gerbils (64 or 320 ng/d of IL-3 versus vehicle in
ischemic gerbils: U 5 10, P ,0.05, or U 5 5, P ,0.01,
respectively [Fig. 1, A–C]).
Effects of IL-3 on the Number of Synapses and Fine Structures of
Pyramidal Neurons in the Hippocampal CA1 Field. In line with
the results of the light microscopic observations and passive
avoidance task, electron microscopy showed that intact
synapses within the stratum moleculare, stratum radiatum,
and stratum oriens of the hippocampal CA1 region were
more numerous in IL-3– than in vehicle-treated ischemic
gerbils (64 ng/d of IL-3 versus vehicle in the stratum radia-
tum of ischemic animals: U 5 12, P ,0.05; 320 ng/d of
IL-3 versus vehicle in the individual strata of ischemic
animals: U 5 7, P ,0.05; U 5 8, P ,0.05; U 5 5, P
,0.01 [Fig. 2 A]). Under light microscopy, vehicle-treated
hippocampal CA1 neurons surviving 7 d after 3-min ischemia
seemed to be intact (Fig. 1 E). However, a careful observa-
tion of the neurons with an electron microscope revealed
that significant numbers of neurons were in the course of
nuclear chromatin fragmentation and/or condensation to
different degrees (Fig. 2, B and C); the nuclei of vehicle-
treated ischemic neurons at early stages of degeneration had
an irregular euchromatin with low electron density com-
pared with intact nuclear euchromatin (Fig. 2 B). On the
other hand, most of the surviving pyramidal neurons in the
CA1 field of IL-3–treated gerbils retained normal morpho-
logical features even 7 d after ischemia (Fig. 2 D). These
findings suggest that IL-3 facilitates the survival of hippo-
campal neurons loaded with ischemic insult in vivo.
Effects of IL-3 on the Number of TUNEL-positive Neurons in
the Hippocampal CA1 Field. TUNEL staining revealed that
many TUNEL-positive neurons were present in the hip-
pocampal CA1 field of 3-min ischemic gerbils with vehicle
infusion 7 d after ischemic insult (Fig. 3 A), suggesting that
irreversible neuronal degeneration was in progress at this
period as deduced from the electron microscopic findings
(Fig. 2, B and C). The 7-d infusion of IL-3 not only pre-
vented delayed neuronal death in the hippocampal CA1
field 7 d after ischemia, but also reduced the number of
TUNEL-positive neurons which were in the course of a
Figure 3. (A–C) Photomicrographs of TUNEL-positive neurons in the hippocampal CA1 field of ischemic gerbils after 7-d infusion of vehicle or IL-3:
vehicle (A); 64 ng/d of IL-3 (B); 320 ng/d of IL-3 (C). The infusion was started 2 h before 3-min ischemia, and continued for 7 d. Note that there were
many TUNEL-positive cells in the hippocampal CA1 field of ischemic gerbils with vehicle infusion. Bar 5 100 mm. (D) The number of TUNEL-posi-
tive neurons in the hippocampal CA1 field of ischemic gerbils. The number of TUNEL-positive neurons in the hippocampal CA1 field of IL-3 (64 or
320 ng/d)-infused ischemic gerbils was less than in vehicle-infused ischemic animals. *P ,0.05; **P ,0.01, Significantly different from the vehicle-
infused ischemic group (statistical significance tested by the two-tailed Mann-Whitney U-test).642 Neurotrophic Activity of IL-3
more delayed degeneration (Fig. 3, B and C). The count of
TUNEL-positive cells in the vehicle-infused ischemic ger-
bils indicated that without IL-3 treatment, nearly one half
of the CA1 neurons surviving 7 d after ischemia undergo a
further degeneration within a few days (Figs. 1 A and 3 D).
IL-3 treatment precluded the late onset of ischemia-induced
neuronal degeneration in a dose-dependent manner (64 or
320 ng/d of IL-3 versus vehicle: U 5 4, P ,0.05, or U 5
0, P ,0.01, respectively [Fig. 3 D]).
Demonstration of IL-3Ra in the Hippocampal CA1 Field.
Although we assumed that IL-3 infused into the left lateral
ventricle reached the hippocampus to rescue ischemic CA1
neurons through its binding to the local receptors, immu-
nohistochemical analysis using the IL-3Ra antibody
showed only scattered positive staining in the hippocampal
CA1 field of sham-operated gerbils (Fig. 4 A), despite an
intense staining in the hippocampal CA3 field, which is
known as a site tolerant to ischemia (Fig. 4 B). Expecting
that IL-3Ra might be abundantly expressed in the hippo-
campal CA1 field of ischemic but not sham-operated gerbils
with vehicle infusion, we investigated the temporal profile
of IL-3Ra expression in the CA1 field during 1–7 d after
3-min ischemia. Occlusion of the common carotid arteries
induced a significant increase in IL-3Ra immunoreactive
neurons at 2 and 4 d after ischemia (Fig. 4, C and D). The
enhanced immunoreactivity of IL-3Ra began to decline 7 d
after ischemia (Fig. 4 E). The IL-3Ra immunoreactions in
the hippocampal CA1 field of ischemic gerbils were com-
pletely abolished by adsorbing the primary antibody with
the homologous antigen (Fig. 4 F). Immunoblot analysis
showed a weak but distinct constitutive expression of IL-
3Ra with a molecular mass of 70 kD in the hippocampal
CA1 field of sham-operated gerbils (Fig. 4 G). The receptor
expression in the field increased at 2 and 4 d after ischemia
(Fig. 4 G). Thus, the transient upregulation of IL-3Ra ex-
pression in a population of hippocampal CA1 neurons after
Figure 4. (A–F) Photomicrographs of IL-3Ra–immunoreactive neurons in the dorsal hippocampus: CA1 field of a sham-operated animal with vehicle
infusion (A); CA3 field of a sham-operated animal with vehicle infusion (B); CA1 field of vehicle-treated animals 2 (C), 4 (D), and 7 (E) d after ischemia;
CA1 field of a sham-operated animal stained with the immunoadsorbed primary antibody (F). Note a significant increase in IL-3Ra–immunoreactive
neurons in the hippocampal CA1 field 2 (C) and 4 d (D) after ischemia. The CA3 field was more intensely labeled with the IL-3Ra antibody than was the
CA1 field at any period examined. (G) Immunoblot analysis of IL-3Ra with a molecular mass of z70 kD in the CA1 field of sham-operated (sham-op)
and ischemic gerbils. 40 mg of protein was loaded onto each lane. Ischemic insult appeared to increase IL-3Ra expression 2 and 4 d after ischemia. (H) CA1
field of an IL-3–infused animal 2 d after ischemia. (I) CA1 field of an IL-3–infused animal 4 d after ischemia. Note that IL-3 infusion caused an apparent
decline in IL-3Ra–immunoreactive CA1 neurons 4 but not 2 d after ischemia. Bar 5 100 mm.643 Wen et al.
ischemic insult may have made it easy for cerebroventricu-
larly infused IL-3 to act on the neurons. The infusion of
IL-3 in ischemic gerbils did not affect IL-3Ra immunore-
activity in the CA1 field (Fig. 4 H), except that 320 ng/d of
IL-3 infusion caused a decline in IL-3Ra–immunoreactive
CA1 neurons at 4 d after ischemia (Fig. 4 I) compared with
immunoreactive CA1 neurons in vehicle-treated ischemic
animals (Fig. 4 D). This finding may reflect downregula-
tion of IL-3R in the CA1 field of ischemic gerbils infused
with the ligand.
Expression of Bcl-xL in the Hippocampal CA1 Field. If bind-
ing to the receptor upregulated transiently after ischemia,
centrally infused IL-3 should transmit signals in favor of
neuronal survival, leading to the generation of neuropro-
tective agents in the CA1 neurons. Among Bcl-2 family
proteins, Bcl-xL protein, which suppresses apoptosis, is
known to be expressed in the mature central nervous sys-
tem, and Bcl-xS protein, which facilitates apoptosis, is
barely detectable in the adult brain (21, 22). Based on the
finding that IL-3 precludes apoptotic death of an erythro-
leukemic cell line by inducing Bcl-2 protein (15), we spec-
ulated that Bcl-xL might be a candidate for the neuropro-
tective agents induced by IL-3 treatment.
In sham-operated gerbils, Bcl-xL mRNA was weakly
and evenly expressed in pyramidal neurons of the CA1-4
fields and in dentate granule cells (Fig. 5 A). Forebrain isch-
emia of 3-min duration caused a selective increase in Bcl-
xL mRNA expression in the hippocampal CA1 field of ger-
bils at 1, 2, and 4 d after ischemic insult (Fig. 5, B and C).
Quantitative analysis showed that relative amount of Bcl-xL
mRNA increased significantly in the CA1 field at 1, 2, and
4 d after ischemia, and thereafter declined to the control
level (Fig. 5 D). No significant changes were observed in
the other regions of the hippocampus. The expressions of
Bcl-2 and Bax mRNAs were not affected by 3-min is-
chemia (data not shown).
In the hippocampal CA1 field of sham-operated gerbils,
Bcl-xL protein with a molecular mass of approximately
29 kD was constitutively expressed (Fig. 5 E). Forebrain
ischemia of 3-min duration caused an apparent decline in
Bcl-xL content in the hippocampal CA1 field of gerbils
treated with vehicle 1 d after ischemic insult, despite the
transient upregulation of Bcl-xL mRNA expression at the
same period (Fig. 5 E). These findings suggest that transla-
tion of Bcl-xL mRNA is suppressed in the hippocampal
CA1 field. On the other hand, IL-3 infusion prevented the
decrease in Bcl-xL protein expression 1 d after ischemia
(Fig. 5 E). There was also a slight increase in Bcl-xL protein
expression in the IL-3–treated hippocampal CA1 region 2 d
after ischemia.
Neurotrophic Effect of IL-3 on Cultured Cortical and Hippo-
campal Neurons. The above in vivo studies suggest that IL-3
prevents delayed neuronal death in the hippocampal CA1
field through a receptor-mediated expression of Bcl-xL
protein. To ascertain this speculation in culture experi-
ments, we investigated (a) whether IL-3 facilitated the sur-
vival of cortical and hippocampal neurons, (b) whether cul-
tured cortical and hippocampal neurons expressed IL-3Ra,
and (c) whether IL-3 treatment induced the expression of
Bcl-xL mRNA and protein in the cultured neurons. Treat-
ment of cultured cortical or hippocampal neurons with IL-3
for 3 d significantly increased the number of surviving neu-
Figure 5. (A–C) Dark-field
photomicrographs showing Bcl-
xL mRNA expression in the hip-
pocampus of sham-operated and
3-min ischemic gerbils: hippo-
campus of a sham-operated ani-
mal (A); hippocampus 1 (B) and
2 (C) d after ischemia. Note a se-
lective increase in Bcl-xL mRNA
expression in the hippocampal
CA1 field 1 and 2 d after
ischemia. Bar 5 200 mm. (D)
Time course of Bcl-xL mRNA
expression in the pyramidal cell
layer of the CA1 field in 3-min
ischemic gerbils. Relative amounts
to the sham-operated control are
expressed as mean 6 SD. *P
,0.05;  **P  ,  0.01,  ***P  ,0.001,
Significantly different from the
control (statistical significance
tested by analysis of variance fol-
lowed by Fisher’s post hoc test).
(E) Immunoblot analysis of Bcl-
xL protein in the CA1 field of
sham-operated (sham-op) and isch-
emic gerbils. Note a marked de-
cline in Bcl-xL protein expression in the vehicle-treated CA1 field 1 d after ischemia, and that IL-3 treatment prevented the decrease in Bcl-xL protein
expression in the CA1 field of ischemic gerbils 1 and 2 d after ischemia.644 Neurotrophic Activity of IL-3
rons compared with the corresponding control culture
without IL-3 treatment. MAP2-positive cortical and hip-
pocampal neurons in the IL-3–treated cultures were more
numerous than in cultures without IL-3 treatment (Fig. 6,
A–E). Subsequent immunoblot analysis showed that the
MAP2-immunoreactive bands of cultured cortical and hip-
pocampal neurons treated with 0.024–15.0 ng/ml of IL-3
(lanes 2–6 in Fig. 6, F and G) were more intense than those
of the control cultures (lane 1 in Fig. 6, F and G). Densito-
metric analysis of the MAP2-immunoreactive bands re-
vealed that IL-3 at concentrations of 0.12–15.0 ng/ml en-
hanced significantly the survival of cultured neurons in a
dose-dependent manner (Fig. 6 H). Immunostaining of
cultured cortical and hippocampal neurons with the IL-
Figure 6. (A–D) Photomicrographs of MAP2-positive neurons in cultures: cortical (A) and hippocampal (B) neuron cultures without IL-3; cortical (C)
and hippocampal (D) neuron cultures treated with 3.0 ng/ml of IL-3. Note that IL-3 significantly increased the number of MAP2-positive neurons. Bar 5
200 mm. (E) Number of MAP2-positive neurons in cultures. The MAP2-positive neurons in the cultures treated with 3.0 ng/ml of IL-3 were more nu-
merous than in the corresponding cultures without IL-3 (control). (F–H) MAP2 immunoblot analysis of IL-3–treated cortical (F) and hippocampal (G)
neurons. Neurons cultured with 0–15.0 ng/ml of IL-3 were immunoblotted with an mAb against MAP2. MAP2-positive bands were observed in neu-
rons without IL-3 treatment (lane 1 in F and G). MAP2-immunoreactive bands increased in intensity in cultures with 0.024–15.0 ng/ml of IL-3 (lanes
2–6 in F and G). Densitometric analysis of MAP2-immunoreactive bands showed that IL-3 enhanced the survival and possibly the neurite extension of
cortical and hippocampal neurons in a dose-dependent manner (H). The data were obtained from four separate cultures and were expressed as a percent-
age of the corresponding control culture without IL-3. (I–K) Photomicrographs of IL-3Ra–immunoreactive neurons in cultures: cortical neuron culture
(I), hippocampal neuron culture (J), and cortical neuron culture stained with the immunoadsorbed primary antibody (K). Note that IL-3Ra immunore-
actions were abolished by adsorbing the primary antibody with the homologous antigen (K). Bar 5 100 mm. (L) Semiquantitative RT-PCR analysis of
Bcl-xL mRNA in cortical neurons cultured in the presence of 0, 1, or 10 ng/ml of IL-3. b-Actin was also amplified as an internal control from each sam-
ple. (M) Immunoblot analysis of Bcl-xL protein in cultured cortical neurons. IL-3 at concentrations of 0.6–15.0 ng/ml apparently induced Bcl-xL expres-
sion in the cultured neurons. The data were obtained from five separate cultures and were expressed as a percentage of the corresponding control culture.
Each value in E, H, and M indicates mean 6 SD. *P ,0.05, **P ,0.01, Significantly different from the corresponding control value (statistical signifi-
cance tested by analysis of variance followed by Fisher’s post hoc test).645 Wen et al.
3Ra antibody showed the presence of IL-3Ra in a large
population of the neurons (Fig. 6, I and J). Pretreatment of
the IL-3Ra antibody with the homologous antigen abol-
ished the immunoreactions (Fig. 6 K). In contrast to the re-
sult of in vivo experiments showing a ligand-induced de-
crease in IL-3Ra–positive CA1 neurons 4 d after ischemia,
we could not detect downregulation of IL-3Ra expression
in cultured neurons in response to IL-3 treatment. This
might be caused by a large number of CA3 neurons con-
tained in the neuronal culture, because the CA3 neurons
exhibited stable IL-3Ra expression.
To investigate the effect of IL-3 on Bcl-xL expression,
we first conducted RT-PCR under quantitative conditions
using specific primers that amplify a 189-bp fragment of the
rat Bcl-xL mRNA. The PCR product showed the ex-
pected size, and its identity was confirmed by direct se-
quencing. Densitometric analysis showed that neurons cul-
tured in the presence of 1 or 10 ng/ml of IL-3 exhibited
Bcl-xL mRNA expression approximately three or six times
as much as control cultured neurons without IL-3 treat-
ment, indicating that IL-3 upregulated Bcl-xL mRNA ex-
pression in a dose-dependent manner (Fig. 6 L). Moreover,
IL-3 at concentrations of 0.6–15.0 ng/ml significantly in-
duced Bcl-xL expression in the cultured neurons (Fig. 6 M).
Neuroprotective Effect of IL-3 on Cultured Neurons Exposed
to FeSO4. We investigated whether or not IL-3 attenu-
ated the damage to cortical and hippocampal neurons by
FeSO4. Cortical and hippocampal neurons were cultured
for 3 d without IL-3 treatment, then FeSO4 was added to
the culture medium. The cortical neurons were no longer
visible within 2 h in the culture, and hippocampal neurons
within 24 h in the culture. MAP2-immunoreactive neu-
rons exposed to FeSO4 (Fig. 7, A and B) were less numer-
ous than in cultures without FeSO4 treatment (Fig. 6, A
and B). Pretreatment with IL-3 protected cortical and hip-
pocampal neurons against lethal damage caused by FeSO4;
MAP2-positive neurons in the IL-3–treated cultures out-
numbered those in cultures without IL-3 pretreatment
(Fig. 7, A–E). However, the protective effect of IL-3 on
the oxidative damage to neurons by FeSO4 was not ob-
Figure 7. (A–D) Photomicrographs of MAP2-positive neurons in cultures exposed to FeSO4: cortical (A) and hippocampal (B) neurons in cultures
treated only with FeSO4; cortical (C) and hippocampal (D) neurons in cultures pretreated with 3.0 ng/ml of IL-3 for 3 d, then treated with FeSO4. Note
that IL-3 treatment significantly increased the number of MAP2-positive neurons. Bar 5 200 mm. (E) Number of MAP2-positive neurons in cultures
exposed to FeSO4. The MAP2-positive neurons in the cultures treated with 3.0 ng/ml of IL-3 were more numerous than in the corresponding control
cultures without IL-3 (FeSO4). (F–H) MAP2 immunoblot analysis of IL-3–treated cortical (F) and hippocampal (G) neurons exposed to FeSO4. Samples
cultured for 3 d with 0–15.0 ng/ml of IL-3 and then treated with FeSO4 were immunoblotted with an mAb against MAP2. Neurons cultured with
FeSO4 but without IL-3 pretreatment showed extremely weak immunoreactive bands (lane 1 in F and G). In neurons treated with 0.12–3.0 ng/ml of IL-3
and then with FeSO4, the intensity of MAP2-immunoreactive bands significantly increased even if FeSO4 existed in the cultures (lanes 3–5 in F and G).
The densitometric analysis of MAP2-immunoreactive bands showed that IL-3 protected the cultured neurons against FeSO4-induced oxidative injuries in
a dose-dependent manner (H). The data were obtained from four separate cultures and were expressed as a percentage of the corresponding control cul-
ture. Each value in E and H indicates mean 6 SD. *P ,0.05, **P ,0.01, ***P , 0.001, Significantly different from the corresponding control value (statis-
tical significance tested by analysis of variance followed by Fisher’s post hoc test).646 Neurotrophic Activity of IL-3
served when IL-3 and FeSO4 were simultaneously added to
the cultured medium (data not shown). This suggests that
IL-3 protects cultured neurons through induction of intra-
cellular antioxidant agents, including a Bcl-2 family pro-
tein(s), rather than by acting alone as a free radical scaven-
ger. Subsequent immunoblot analysis showed that the
MAP2 bands of neurons exposed to FeSO4 without IL-3
pretreatment were very thin (lane 1 in Fig. 7, F and G). In
contrast, intense MAP2 bands were detected in neurons in
cultures treated with IL-3 at concentrations of 0.12–3.0
ng/ml before the exposure to FeSO4 (lanes 3–5 in Fig. 7, F
and G). The neuroprotective action of IL-3 at different
concentrations was quantitatively evaluated by densitomet-
ric analysis of the immunoreactive bands (Fig. 7 H). Pre-
treatment with IL-3 protected significantly cultured neu-
rons against FeSO4-induced damage in a dose-dependent
manner. The most effective concentration was 0.6–3.0 ng/ml
for hippocampal and cortical neurons (Fig. 7 H). Thus,
these in vitro studies suggest that IL-3 exerts a protective
effect on cultured neurons through binding to the cell sur-
face receptor, leading to the induction of Bcl-xL protein,
which possibly counteracts the neurotoxicity of free radi-
cals.
Discussion
Among the subregions of the gerbil hippocampus, the
CA1 field is the most vulnerable to ischemia (52), although
the other subregions in rats exposed to intermittent stress
or physiological concentrations of glucocorticoids are also
easily damaged by an excitotoxin kainic acid and by brain
ischemia (27, 53). The hippocampal CA3 field of the rat
appears to be selectively susceptible to prolonged glucocor-
ticoid exposure (54). In cases of brain ischemia, CA1 neu-
rons with N-methyl-d-aspartate receptor exhibit sustained
elevation of intracellular Ca21 concentration as elicited by
an ischemia-induced increase in extracellular glutamate
concentration, and such excessive Ca21 loading to the CA1
but not CA3 neurons is considered to trigger the activa-
tions of various enzymes and genes facilitating neuron
death (30, 55–57). It is also plausible that transient forebrain
ischemia modulates the production of peptide growth fac-
tors and certain cytokines, including IL-6 (58–61), thereby
affecting ischemic damage to the CA1 neurons. We specu-
late that there are multiple endogenous mediators regulat-
ing neuronal death or survival in the ischemic brain, since a
variety of drugs and peptide growth factors possibly with
different action mechanisms have been shown to prevent
delayed neuronal death in the hippocampal CA1 field (23–
25, 36–38, 49). Nevertheless, apart from studies dealing
with the disrupted calcium homeostasis in the ischemic
CA1 region (30, 56, 57), no previous studies have ad-
dressed the question of why hippocampal CA1 neurons are
selectively vulnerable to brain ischemia. In this immuno-
histochemical study using an IL-3Ra antibody, we noted
that IL-3Ra expression was barely detectable in the hip-
pocampal CA1 field of sham-operated gerbils and was ap-
parently upregulated 2 and 4 d after 3-min ischemia. How-
ever, the IL-3Ra immunoreactivity in the hippocampal
CA1 field, even though upregulated in response to isch-
emic insult, was still less intense than that in the hippo-
campal CA3 field, which is known as a site tolerant to isch-
emia. The paucity of IL-3Ra in the CA1 field appears to
account, in part, for the selective vulnerability of hippo-
campal CA1 neurons to brain ischemia, provided that the
ligand is produced equally in the CA1 and CA3 fields.
Since there is no information on the localization of IL-3 in
the brain tissue, a more sensitive IL-3 assay system will be
needed to detect the central production of IL-3 in vivo.
Unlike CA3 pyramidal neurons, only a limited popula-
tion of CA1 neurons was labeled with the IL-3Ra anti-
body even after ischemia. In support of this finding, the
continuous cerebroventricular infusion of IL-3 rescued
many but not all ischemic CA1 neurons, and prevented
significantly but not completely the occurrence of isch-
emia-induced learning disability as revealed by the step-
down passive avoidance task. The precise mechanism by
which centrally infused IL-3 supports ischemic CA1 neu-
rons in vivo is beyond the scope of this discussion. In the
hippocampal CA1 region of vehicle-treated gerbils with
3-min ischemia, Bcl-xL mRNA expression was upregulated
at 1, 2, and 4 d after ischemia without leading to translation
of Bcl-xL protein. This suggests that the impaired transla-
tion of Bcl-xL mRNA is, in part, responsible for neuron
death in the ischemic hippocampal CA1 field. On the basis
of our immunoblot analysis, IL-3 is likely to enhance the
survival of ischemic CA1 neurons by stimulating the ex-
pression of Bcl-xL protein, which is known to inhibit apop-
totic neuron death in cultures (18, 20) and possibly in the
mature brain (21, 22).
Under electron microscopy, we noticed that vehicle-
treated CA1 neurons which appeared to be intact at the
light microscopic level exhibited pathological changes in
the nuclear chromatin 7 d after ischemia. This prompted us
to conduct TUNEL staining in paraffin sections from IL-3–
and vehicle-treated ischemic gerbils. In the conventional
5-min ischemia, where brain temperature is not kept at
37.0 6 0.28C during ischemia, TUNEL-positive CA1
neurons have been shown to peak 4 d after ischemic insult,
and only a few are visible 7 d after ischemia, possibly due
to the so-called delayed death of almost all CA1 neurons at
this period (62). In contrast, in the present study, the vehi-
cle-treated normothermic gerbils with 3-min ischemia ex-
hibited many TUNEL-positive neurons in the hippocam-
pal CA1 field even 7 d after ischemia. This finding suggests
that the hippocampal CA1 field loaded with 3-min isch-
emia undergoes a progressive degeneration slower than
with 5-min ischemia. Thus, this animal model with an epi-
sode of 3-min ischemia has a wider therapeutic window
than the conventional 5-min ischemia model (52) and may
be useful for the screening of neuroprotective agents. In
this study, IL-3 treatment reduced dramatically the number
of TUNEL-positive neurons in 3-min ischemic gerbils.
This indicates that the slowly progressive degeneration of647 Wen et al.
hippocampal CA1 neurons in vehicle-treated ischemic ger-
bils is markedly inhibited by IL-3 even after the termina-
tion of its infusion. Thus, in situ detection of DNA frag-
mentation by TUNEL staining appears to be a reliable tool
for assessing the effects of neuroprotective agents on the
late degeneration of hippocampal CA1 neurons in ischemic
gerbils. We speculate that a brief ischemic insult similar to
3-min ischemia in gerbils is occasionally loaded to the hu-
man brain, leading to sustained neuronal damage of the isch-
emic focus. If this is the case, continuous treatment with
peptide growth factors (23–25, 36) or nonpeptide neuro-
protective agents (37, 38, 49) will be needed to lessen
slowly progressive ischemic neuronal damage.
In line with the results of the in vivo experiments, these
in vitro studies demonstrated that IL-3 enhances the sur-
vival of cultured neurons possibly through binding to the
cell surface receptor, and induces Bcl-xL mRNA and pro-
tein expression in a concentration-dependent manner. IL-3
also attenuated neuronal damage caused by free radicals
(possibly hydroxyl radicals), which are known to be over-
produced during and after brain ischemia (28, 32–34).
In conclusion, IL-3 protects neurons against ischemia/
reperfusion injury and oxidative stress through a receptor-
mediated increase in Bcl-xL expression, which suppresses
neuronal cell death. IL-3 exerts a trophic action on hippo-
campal neurons in vivo and in vitro.
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